NetScientific - Advancing on multiple fronts to commercialisation
NetScientific recently announced full-year results for 2017. It was a year of progress for the company, which is carrying forward into 2018. In February 2018, ProAxsis had its first commercial sale of Neutrophil Elastase Airways Test (NEATstik) for measuring active neutrophil elastase, in this case to a research lab conducting a respiratory clinical trial with a pharmaceutical company. In March, Vortex announced a collaboration with BioView for automated clinical biomarker identification of circulating tumour cells.NetScientific is a healthcare IP commercialization group focused on sourcing, funding and commercializing technologies and companies that have the potential to treat chronic disease. As of Dec 31 2016, Co. had four core portfolio companies: Vortex Biosciences, Inc., which is developing a liquid biopsy technology that aims to improve cancer diagnosis, monitoring and treatment; Wanda, Inc., which has developed an artificial intelligence platform for remote patient monitoring; ProAxsis Ltd, which is developing a range of products for the capture, detection and measurement of active protease biomarkers of disease; and Glycotest, Inc., which is a liver diagnostics company.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.